When was Palladio Biosciences founded?

Palladio Biosciences was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Palladio Biosciences located?

Palladio Biosciences is headquartered in Newtown Square, United States.

How many employees does Palladio Biosciences have?

As of Jul 01, 2024, the latest employee count at Palladio Biosciences is 20.

Is Palladio Biosciences a funded company?

Palladio Biosciences is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 25, 2020.

When was the latest funding round of Palladio Biosciences?

Palladio Biosciences' latest funding was a $***** Series B round on Sep 25, 2020, with participation from 4 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $711M in funding in 2026 to date.

Where does Palladio Biosciences rank among its competitors?

Palladio Biosciences ranks 63rd amongst 106 active competitors, of which 38 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Palladio Biosciences?

Palladio Biosciences' top competitors include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Palladio Biosciences - 2026 Company Profile, Funding & Competitors

Company Details

Palladio Biosciences is developing medicines for orphan diseases of kidney including Polycystic kidney disease (PKD). Its lead product is lixivaptan, a selective vasopressin V2 receptor antagonist in development for the treatment of polycystic kidney disease (Phase 2).

Website: palladiobio.com
Email ID: *****@palladiobio.com

Key Metrics

Founded Year

2016

Location

Newtown Square, United States

Stage

Deadpooled

Total Funding

$28M in 1 round

Latest Funding Round

Series B, Sep 25, 2020, $*****

Investors

Samsara BioCapital & 3 more

Ranked

63^rd among 106 active competitors

Employee Count

20 as on Jul 01, 2024

Similar Companies

BioMarin Pharmaceutical & 128 more

View Palladio Biosciences' full profile

Palladio Biosciences has raised a total funding of $28M over 1 round. Its latest funding round was a Series B round on Sep 25, 2020 for $*****. 4 investors participated in its latest round. Palladio Biosciences has 4 institutional investors.

Here is the list of recent funding rounds of Palladio Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 25, 2020	4755908	Series B	6850058	2894681	2631668	8743305

Access funding benchmarks and valuations. Sign up today!

View details of Palladio Biosciences's funding rounds and investors

Palladio Biosciences' employee count trend

Palladio Biosciences has 20 employees as of Jul 24. Here is Palladio Biosciences's employee count trend over the years:

Employee count trend for Palladio Biosciences

Uncover Palladio Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Palladio Biosciences include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Here is the list of Top 10 competitors of Palladio Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Pfizer & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
3rd	Pharvaris 2015, Leiden (Netherlands), Public	Orally deliverable bradykinin B2 antagonists for hereditary angioedema	$164M	Foresite Capital, Life Sciences Partners & 9 others	67/100
4th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Deerfield & 9 others	64/100
5th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
6th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Venrock & 9 others	63/100
7th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
8th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Gilde Healthcare & 7 others	61/100
9th	American Gene 2008, Rockville (United States), Series B	Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases	$53.1M	Ride wave ventures, Gaingels & 4 others	60/100
10th	Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised	Small molecule drug reformulation and repurposing for orphan indications	-	robinson-family.ca, Michael A Tory Trust ... & 31 others	59/100
63rd	Palladio Biosciences 2016, Newtown Square (United States), Deadpooled	Medicines for orphan diseases of kidney including Polycystic kidney disease (PKD)	$28M	Samsara BioCapital, Osage University Partners ... & 2 others	33/100